367 related articles for article (PubMed ID: 11171994)
1. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor.
Haase VH; Glickman JN; Socolovsky M; Jaenisch R
Proc Natl Acad Sci U S A; 2001 Feb; 98(4):1583-8. PubMed ID: 11171994
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice.
Rankin EB; Higgins DF; Walisser JA; Johnson RS; Bradfield CA; Haase VH
Mol Cell Biol; 2005 Apr; 25(8):3163-72. PubMed ID: 15798202
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of the tumor suppressor gene von Hippel-Lindau (VHL) in granulocytes contributes to development of liver hemangiomas in a mouse model.
Bader HL; Hsu T
BMC Cancer; 2016 Oct; 16(1):797. PubMed ID: 27733136
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
5. Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia.
Pastore Y; Jedlickova K; Guan Y; Liu E; Fahner J; Hasle H; Prchal JF; Prchal JT
Am J Hum Genet; 2003 Aug; 73(2):412-9. PubMed ID: 12844285
[TBL] [Abstract][Full Text] [Related]
6. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.
Siemeister G; Weindel K; Mohrs K; Barleon B; Martiny-Baron G; Marmé D
Cancer Res; 1996 May; 56(10):2299-301. PubMed ID: 8625303
[TBL] [Abstract][Full Text] [Related]
7. The von Hippel-Lindau tumor suppressor gene.
Kondo K; Kaelin WG
Exp Cell Res; 2001 Mar; 264(1):117-25. PubMed ID: 11237528
[TBL] [Abstract][Full Text] [Related]
8. Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene.
Ma W; Tessarollo L; Hong SB; Baba M; Southon E; Back TC; Spence S; Lobe CG; Sharma N; Maher GW; Pack S; Vortmeyer AO; Guo C; Zbar B; Schmidt LS
Cancer Res; 2003 Sep; 63(17):5320-8. PubMed ID: 14500363
[TBL] [Abstract][Full Text] [Related]
9. von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids.
Lieubeau-Teillet B; Rak J; Jothy S; Iliopoulos O; Kaelin W; Kerbel RS
Cancer Res; 1998 Nov; 58(21):4957-62. PubMed ID: 9810005
[TBL] [Abstract][Full Text] [Related]
10. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice.
Gnarra JR; Ward JM; Porter FD; Wagner JR; Devor DE; Grinberg A; Emmert-Buck MR; Westphal H; Klausner RD; Linehan WM
Proc Natl Acad Sci U S A; 1997 Aug; 94(17):9102-7. PubMed ID: 9256442
[TBL] [Abstract][Full Text] [Related]
11. Tracheal development and the von Hippel-Lindau tumor suppressor homolog in Drosophila.
Adryan B; Decker HJ; Papas TS; Hsu T
Oncogene; 2000 Jun; 19(24):2803-11. PubMed ID: 10851083
[TBL] [Abstract][Full Text] [Related]
12. Von Hippel-Lindau syndrome. A pleomorphic condition.
Friedrich CA
Cancer; 1999 Dec; 86(11 Suppl):2478-82. PubMed ID: 10630173
[TBL] [Abstract][Full Text] [Related]
13. VHL and PTEN loss coordinate to promote mouse liver vascular lesions.
Chen S; Sanford CA; Sun J; Choi V; Van Dyke T; Samulski RJ; Rathmell WK
Angiogenesis; 2010 Mar; 13(1):59-69. PubMed ID: 20221685
[TBL] [Abstract][Full Text] [Related]
14. Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis.
de Paulsen N; Brychzy A; Fournier MC; Klausner RD; Gnarra JR; Pause A; Lee S
Proc Natl Acad Sci U S A; 2001 Feb; 98(4):1387-92. PubMed ID: 11171960
[TBL] [Abstract][Full Text] [Related]
15. Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Marti HH; Plate KH
Blood; 1998 Nov; 92(9):3388-93. PubMed ID: 9787178
[TBL] [Abstract][Full Text] [Related]
16. [Von Hippel-Lindau disease].
Shuin T; Ashida S; Yao M; Kanno H
Nihon Rinsho; 2000 Jul; 58(7):1448-54. PubMed ID: 10921322
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling.
Wykoff CC; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ
Oncogene; 2000 Dec; 19(54):6297-305. PubMed ID: 11175344
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility to vascular neoplasms but no increased susceptibility to renal carcinogenesis in Vhl knockout mice.
Kleymenova E; Everitt JI; Pluta L; Portis M; Gnarra JR; Walker CL
Carcinogenesis; 2004 Mar; 25(3):309-15. PubMed ID: 14604887
[TBL] [Abstract][Full Text] [Related]
19. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients.
Lubensky IA; Gnarra JR; Bertheau P; Walther MM; Linehan WM; Zhuang Z
Am J Pathol; 1996 Dec; 149(6):2089-94. PubMed ID: 8952541
[TBL] [Abstract][Full Text] [Related]
20. Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity.
Blankenship C; Naglich JG; Whaley JM; Seizinger B; Kley N
Oncogene; 1999 Feb; 18(8):1529-35. PubMed ID: 10102622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
